The discovery and development of SU14813, a next-generation multitargeted tyrosine kinase inhibitor for the treatment of human malignancies.

Commentary on: [Shem Patyna, A. Douglas Laird, Dirk B. Mendel, Anne-Marie O'Farrell, Chris Liang, Huiping Guan, Tomas Vojkovsky, Stefan Vasile, Xueyan Wang, Jeffrey Chen, Maren Grazzini, Cheng Y. Yang, Joshua O. Haznedar, Juthamas Sukbuntherng, Wei-Zhu Zhong, Julie M. Cherrington, and Dana Hu-